Epithalon

Users on peptide forums commonly say they feel nothing right away. When people do report a change, it's usually in sleep within the first week or two, such as falling asleep more easily or having more vivid dreams. These are user reports. The one randomized trial measured a melatonin metabolite in urine and didn't assess sleep, and no study has tested epithalon in people with insomnia.

No, and it isn't the best-studied approach either. The protocol users describe, 10 mg a day for 10 days repeated about every six months, is community practice; we couldn't trace it to a published epithalon study. Some users say the 10 mg figure came from epithalamin dosing, but that's unverified forum lore. The only randomized human study (Ivko 2021) gave 0.5 mg a day as a sublingual spray for 20 days to women with low melatonin output. FDA's 2026 review notes that websites cite 5-10 mg a day by injection or orally, and many users now describe 0.5-1 mg a day. No injected dose has been tested in people.

There's no study-based timeline. Users most often mention sleep changes within 1-2 weeks, but that's self-report. In the randomized study, the melatonin metabolite was measured after 20 days. Claims about skin, immunity or slower aging come from vendors, clinics, cell studies and studies of the extract epithalamin; no human study of epithalon has measured them.

Nobody knows yet. As of October 2026, FDA's review for its compounding advisory committee found no clinical studies assessing epithalon's safety in people and no repeat-dose toxicity studies in animals. FDA's adverse-event databases held no reports, which says little because FDA doesn't receive every report, especially for unapproved products. FDA also raised a theoretical concern: epithalon activates telomerase, longer telomeres are linked to cancer, so long-term exposure could be carcinogenic, and the short mouse studies that reported fewer tumors don't settle the question. Users mostly report injection-site irritation and occasional headache or vivid dreams. The decades of Russian research often cited for safety largely used the extract epithalamin. In July 2026 the committee voted 7-4, with one abstention, to recommend epithalon for the 503A bulks list for insomnia; as of October 2026 FDA hasn't acted on that vote. This information is for research purposes only; anyone considering personal use should talk to a healthcare professional.